MOACM
CORT icon

Mutual of America Capital Management’s Corcept Therapeutics CORT Stock Holding History

Mutual of America Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$432K Buy
10,714
+14
+0.1% +$523 ﹤0.01% 1098
2025
Q4 		$372K Sell
10,700
-147,618
-93% -$11.6M ﹤0.01% 1138
2025
Q3 		$13.2M Buy
158,318
+2,076
+1% +$150K 0.14% 126
2025
Q2 		$11.5M Sell
156,242
-53,116
-25% -$3.85M 0.12% 153
2025
Q1 		$23.9M Sell
209,358
-10,547
-5% -$642K 0.28% 42
2024
Q4 		$11.1M Sell
219,905
-38,848
-15% -$2.04M 0.12% 145
2024
Q3 		$12M Sell
258,753
-4,543
-2% -$161K 0.13% 135
2024
Q2 		$8.55M Buy
263,296
+128,194
+95% +$3.51M 0.09% 202
2024
Q1 		$3.4M Sell
135,102
-9,870
-7% -$233K 0.04% 669
2023
Q4 		$4.71M Buy
144,972
+36,255
+33% +$996K 0.05% 478
2023
Q3 		$2.96M Sell
108,717
-7,367
-6% -$213K 0.04% 678
2023
Q2 		$2.58M Sell
116,084
-9,586
-8% -$221K 0.03% 801
2023
Q1 		$2.72M Buy
125,670
+11,913
+10% +$261K 0.03% 772
2022
Q4 		$2.31M Buy
113,757
+2,370
+2% +$59.4K 0.03% 843
2022
Q3 		$2.86M Buy
111,387
+95,327
+594% +$2.55M 0.04% 686
2022
Q2 		$382K Buy
16,060
+2,322
+17% +$50.6K ﹤0.01% 1153
2022
Q1 		$309K Buy
13,738
+783
+6% +$16.7K ﹤0.01% 1209
2021
Q4 		$257K Sell
12,955
-958
-7% -$19.4K ﹤0.01% 1279
2021
Q3 		$274K Sell
13,913
-1,010
-7% -$21.1K ﹤0.01% 1253
2021
Q2 		$328K Buy
14,923
+823
+6% +$18.3K ﹤0.01% 1250
2021
Q1 		$335K Buy
14,100
+1,047
+8% +$28K ﹤0.01% 1227
2020
Q4 		$341K Buy
13,053
+570
+5% +$12K ﹤0.01% 1170
2020
Q3 		$217K Buy
12,483
+7,438
+147% +$119K ﹤0.01% 1209
2020
Q2 		$85K Buy
5,045
+506
+11% +$7.11K ﹤0.01% 1211
2020
Q1 		$54K Buy
4,539
+839
+23% +$10.4K ﹤0.01% 1269
2019
Q4 		$45K Sell
3,700
-86
-2% -$1.2K ﹤0.01% 1373
2019
Q3 		$54K Buy
3,786
+29
+0.8% +$356 ﹤0.01% 1320
2019
Q2 		$42K Buy
3,757
+777
+26% +$8.66K ﹤0.01% 1382
2019
Q1 		$35K Buy
2,980
+341
+13% +$4.24K ﹤0.01% 1378
2018
Q4 		$35K Buy
2,639
+632
+31% +$8.35K ﹤0.01% 1320
2018
Q3 		$28K Buy
2,007
+1,656
+472% +$23.1K ﹤0.01% 1389
2018
Q2 		$6K Buy
+351
New +$6.11K ﹤0.01% 1332

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Mutual of America Capital Management's CORT Position: Q1 2026 in Review

Mutual of America Capital Management increased its Corcept Therapeutics (CORT) stake by 0.13% in Q1 2026, buying an estimated $523 and bringing the position to 10,714 shares worth $432K. The position accounts for ﹤0.01% of the portfolio, ranked #1098.

Mutual of America Capital Management first reported a position in CORT in Q2 2018 and has held it in 32 quarters since. The position peaked at $23.9M in Q1 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Mutual of America Capital Management held 10,714 shares of Corcept Therapeutics worth $432K as of Q1 2026.
  • Mutual of America Capital Management bought 14 Corcept Therapeutics shares in Q1 2026, an estimated $523.
  • Corcept Therapeutics made up ﹤0.01% of Mutual of America Capital Management's portfolio in Q1 2026, its #1098 holding.
  • Mutual of America Capital Management first reported a position in Corcept Therapeutics in Q2 2018 and has held it in 32 quarters since.
  • Mutual of America Capital Management's Corcept Therapeutics position peaked at $23.9M in Q1 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Mutual of America Capital Management's 13F filing for Q1 2026, filed 7 May 2026.